{"id":4592,"date":"2024-07-11T13:16:29","date_gmt":"2024-07-11T03:16:29","guid":{"rendered":"\/eu-uk\/?p=4592"},"modified":"2024-07-11T13:16:43","modified_gmt":"2024-07-11T03:16:43","slug":"orthocell-receives-regulatory-approval-to-commence-sales-of-striate-in-canada","status":"publish","type":"post","link":"\/eu-uk\/blog\/2024\/07\/11\/orthocell-receives-regulatory-approval-to-commence-sales-of-striate-in-canada\/","title":{"rendered":"Orthocell Receives Regulatory Approval to Commence Sales of Striate+\u2122 in Canada\u00a0"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Orthocell has received a Medical Device Licence from Health Canada, allowing the commencement of sales of its market leading dental guided bone regeneration product, Striate+\u2122, in the key market of Canada.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The Canadian market for Striate+ is estimated to be worth A$60 million and the global market opportunity for these products is estimated to be in excess of A$1 billion.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Orthocell\u2019s distribution partner for Striate+, BioHorizons, is already well established in the Canadian market which will facilitate a fast transition to first sales and revenue generation from this region.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Orthocell Managing Director, Paul Anderson, said:\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u201cCanadian approval for Striate+\u2122 is further validation of Orthocell\u2019s expanding global footprint. Approval in this market complements our FDA approval and strengthens the Company&#8217;s position to increase revenue, in collaboration with our valued partner BioHorizons. Additionally, it reaffirms the high quality of our product and world-class, scalable manufacturing process.\u201d<\/span><\/p>\n<p><a href=\"https:\/\/bit.ly\/OCC-Canada\"><span style=\"font-weight: 400;\">Click here to read the ASX release.<\/span><span style=\"font-weight: 400;\">\u00a0<\/span><\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Orthocell has received a Medical Device Licence from Health Canada, allowing the commencement of sales of its market leading dental guided bone regeneration product, Striate+\u2122, in the key market of Canada.<\/p>\n","protected":false},"author":2,"featured_media":4593,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-4592","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news"],"aioseo_notices":[],"_links":{"self":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4592","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/comments?post=4592"}],"version-history":[{"count":2,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4592\/revisions"}],"predecessor-version":[{"id":4595,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4592\/revisions\/4595"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/media\/4593"}],"wp:attachment":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/media?parent=4592"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/categories?post=4592"},{"taxonomy":"post_tag","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/tags?post=4592"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}